Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

November 25, 2025

New analysis examines RAP-219's effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure severity

BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that the Company will present the results of its Phase 2a trial of RAP-219 in focal onset seizures (FOS), along with new efficacy analysis, at the upcoming 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5–9, 2025, in Atlanta.

The Company will present during the meeting's poster sessions and will also host a dedicated Scientific Exhibit Room highlighting the RAP-219 clinical program. In addition to topline efficacy and safety data from its Phase 2a FOS trial, new data on RAP-219's effect during the first month of treatment and consistency of efficacy over the entire treatment period, the effect of baseline disease severity on efficacy outcomes, and the effect of RAP-219 on seizure severity will be presented. The full schedule of Rapport posters at AES is as follows:

Poster Session Presentation Details:

- **Abstract Title:** Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Associated Protein: Impact on RNS Long Episodes and Focal Seizures
  Poster: 2.489
  Date: Sunday, December 7, 2025
  Time: 10:00 a.m. – 4:00 p.m. ET

- **Abstract Title:** RAP-219: A Differentiated ASM Targeting Restricted Brain Expression of Transmembrane AMPA Receptor Protein γ8
  Poster: 3.355
  Date: Monday, December 8, 2025
  Time: 8:00 a.m. – 2:00 p.m. ET

Scientific Exhibit Room Details:

Date: Sunday, December 7, 2025
Time: 8:00 – 11:00 a.m. ET
Location: GWCC B303, Level 3

The Exhibit Room will feature the posters listed above, along with the following additional posters:

- Effect of RAP-219 on Long Episodes and Clinical Seizures in Adults with Drug-Resistant Focal Seizures and an Implanted Responsive Neurostimulator (RNS) System by Baseline Long Episode and Clinical Seizure Frequencies: A Post Hoc Analysis of a Phase 2a Proof-of-Concept Study
- Effect of RAP-219 on Seizure Severity in Adults with Drug-Resistant Focal Seizures and an Implanted Responsive Neurostimulator (RNS) System: Analysis of a Phase 2a Proof-of-Concept Study
- Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Volunteers
- Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the γ8 Transmembrane AMPA Receptor-Associated Regulatory Protein (TARPγ8)
- Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency
- Evolution of RAP-219 for the Treatment of Epilepsy

Following the conference, the Rapport AES posters will be available within the Publications section of the Company's website.

About RAP-219
RAP-219 is a potential first-in-class, clinical-stage TARPγ8-specific AMPA receptor (AMPAR) negative allosteric modulator (NAM).

Whereas AMPARs are distributed widely in the central nervous system, the receptor associated protein (RAP) TARPγ8 is expressed only in discrete brain regions, including the hippocampus and neocortex, where focal seizures often originate. By contrast, TARPγ8 has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events. With this precision approach, the Company believes RAP-219 has the potential to provide a differentiated profile as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8, the Company believes RAP-219 has pipeline-in-a-product potential and is evaluating the compound as a transformational treatment for patients with focal onset seizures, bipolar disorder, and peripheral neuropathic pain.

About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company's founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport's RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Availability of Other Information About Rapport Therapeutics
Rapport Therapeutics uses and intends to continue to use its Investor Relations website and LinkedIn (Rapport Therapeutics) as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website and LinkedIn, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts. The contents of the Company's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of RAP-219 for the treatment of drug-resistant focal onset seizures, including the initiation, timing, progress, results and future data releases of our ongoing and planned clinical trials; and expectations for the efficacy, tolerability, and commercial potential of RAP-219.

Forward looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect Rapport's business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company's research and development activities; Rapport's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company's dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Rapport's ability to attract, integrate and retain key personnel; risks related to the Company's financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport's intellectual property protections; and risks related to the competitive landscape for Rapport's product candidates; as well as other risks described in "Risk Factors," in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Rapport's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com